• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results

    3/28/24 4:05:00 PM ET
    $TBIO
    Biotechnology: Laboratory Analytical Instruments
    Industrials
    Get the next $TBIO alert in real time by email

    SAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, today announced financial results for the fourth quarter and year ended December 31, 2023. Results highlight strong BioXp® kit sales, expanding gross margin and reduced operating expense.

    In discussing the results, Todd R. Nelson Ph.D., Founder and CEO of Telesis Bio said, "I'm pleased with our operating execution in a challenging macro environment during 2023. Our company experienced record BioXp kits sales and expanding gross margin against the backdrop of significant cost cutting initiatives undertaken to align our operating structure with our strategic vision for growth. We believe that our rapid and flexible mRNA synthesis kits are game-changing and unlock tremendous value by providing customers control over their screening and discovery on timelines that were not possible previously."

    Highlights

    • BioXp® kit revenue for the fourth quarter of 2023 exceeded $1.0 million, the highest level in the history of the Company, an increase of 59.6% from the prior quarter and 25.9% compared to the same quarter in 2022. This increase was driven by rapid adoption of highly differentiated mRNA workflows, which grew at more than 300% compared to the same quarter in 2022. For the full 2023 fiscal year, BioXp kit sales increased 10% compared to the prior year.
    • Total consolidated revenue for 2023 was $27.5 million, up slightly from $27.4 million achieved in 2022. Total revenue, excluding BioXp instrument sales and discontinued BioFoundry Services operations, was $20.9 million for the full-year period, an increase of 12.4% compared to $18.6 million for the same categories in the prior year.
    • Collaboration revenue for the year, driven in part by the successful achievement of several key technology milestones, was $8.7 million, an increase of 30.7% above the prior year's collaboration revenue of $6.7 million.
    • Industry-wide acceptance of mRNA technology has driven the Company's launch of BioXp mRNA de novo synthesis kits and rapid cell-free RNA synthesis solutions. These products enable customers to accelerate cell and gene therapy, vaccine and antibody discovery, and state of the art development workflows. The Company anticipates that use of RNA in drug discovery workflows will continue to grow, and it intends to prioritize continuing development of the capabilities of its highly differentiated BioXp and SOLA platforms to these workflows.
    • In 2023, the Company undertook cost reduction activities to achieve significant reductions to its overall cost structure. For full-year 2023, exclusive of non-cash goodwill impairment, operating expense was $52.1 million, a reduction of 16.1% from the prior year's operating expense level of $62.1 million. For the fourth quarter of 2023, exclusive of non-cash goodwill impairment, operating expense was $10.8 million, a reduction of 24.4% from the prior year's fourth quarter level of $14.3 million. Some of these cost reductions were completed late in the year and are not fully reflected in results for the fourth quarter of 2023. Such reductions are expected to result in favorable reductions to operating expense in 2024.
    • During 2023 the Company's program to insource supply of oligos was completed and internal production now has the capacity to supply at least 70% of the Company's ongoing oligo needs. Further, the Company has completed efforts to insource instrument manufacturing. Both efforts are expected to favorably impact gross margin and product quality in 2024.
    • In other recent highlights, the Company continues to pursue activities under its strategic research collaboration and license agreement with Pfizer. This program is based upon Telesis' proprietary SOLA platform which utilizes enzymatic DNA synthesis technology for potential application by Pfizer in mRNA-based vaccines and other biopharma products.

    Summary of Fourth Quarter and Full Year 2023 Financial Results

    Revenue of $7.0 million for the fourth quarter of 2023 was down compared to $9.5 million for the same period in the prior year due to continued capital spending weakness gripping the entire industry and the resulting mix-shift toward lower-priced BioXp 3250 instruments. Revenue for the year ended December 31, 2023 was $27.5 million, compared to $27.4 million for the prior year. The increase of $0.1 million was driven by an increase in collaboration and royalty revenue of $2.1 million, offset by a decrease in product and service revenue of $2.0 million.

    Gross margin at 68.1% for the fourth quarter of 2023 was flat from 68.1% for the same period in the prior year. On an annual basis, gross margin was 61.6% and 56.8% for the years ended December 31, 2023 and 2022, respectively. This increase was driven by improving product mix, an increase in high margin collaboration revenue, and early contribution from oligo insourcing which achieved production status in the fourth quarter and demonstrated the capacity to internally fulfill more than 70% of the Company's oligo supply needs.

    Exclusive of a $11.4 million fourth quarter 2023 non-cash charge for goodwill impairment, total operating expense for the quarter was $10.8 million, a $3.5 million or 24.4% reduction from the fourth quarter of 2022. A restructuring program in the fourth quarter of 2023 largely resulted in the year-over-year reduction in operating expense. This restructuring saw consolidated Telesis headcount fall from an October month-end level of 190 employees to 138 employees by the end of the year. For the full year 2023, exclusive of non-cash goodwill impairment, operating expense was $52.1 million compared to $62.1 million in the prior year. All categories contributed to the year-over-year reduction of $10.0 million or 16.1%.

    During the fourth quarter of 2023 the Company recorded a goodwill impairment charge of $11.4 million. As of December 31, 2023, this charge reduced the carrying amount of goodwill to $3.5 million. For the year ended December 31, 2022, the Company did not record any impairment of goodwill.

    Net loss was $18.3 million for the fourth quarter of 2023, compared to a loss of $8.1 million in the same period in the prior year. Net loss per share was $0.61 for the fourth quarter of 2023, compared to $0.28 for the corresponding prior year period. For the year ended December 31, net loss was $49.0 million in 2023 compared to $48.5 million for the same period in the prior year. Per share net loss results were $1.64 and $1.65 in 2023 and 2022, respectfully.

    As of December 31, 2023, cash, cash equivalents, restricted cash, and investments were $19.3 million, and long-term notes payable was $5.3 million. In November 2023, the Company repaid $15.0 million under its 2022 Term Loan Agreement.

    The Company will not be issuing additional forward-looking guidance at this time.

    About Telesis Bio

    Telesis Bio is empowering scientists with the ability to create novel, synthetic biology-enabled solutions for many of humanity's greatest challenges. As inventors of the industry-standard Gibson Assembly® method and the first commercial automated benchtop DNA and mRNA synthesis system, Telesis Bio is enabling rapid, accurate and reproducible writing of DNA and mRNA for numerous downstream markets. The award-winning BioXp® system consolidates, automates, and optimizes the entire synthesis, cloning and amplification workflow. As a result, it delivers virtually error-free synthesis of DNA and RNA at scale within days and hours instead of weeks or months. Scientists around the world are using the technology in their own laboratories to accelerate the design-build-test paradigm for novel, high-value products for precision medicine, biologics drug discovery, vaccine and therapeutic development, genome editing, and cell and gene therapy. Telesis Bio is a public company based in San Diego. For more information, visit www.telesisbio.com. Telesis Bio, the Telesis Bio logo, Gibson Assembly, and BioXp are trademarks of Telesis Bio Inc.

    Forward-Looking Statements

    This press release contains forward-looking statements. All statements other than statements of historical facts contained herein are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These statements include statements and guidance regarding Telesis Bio's future financial performance as well as statements regarding the future release and success of new and existing products and services. Such statements are based on current assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially from current expectations. These risks and uncertainties, many of which are beyond our control, include risks described in the section entitled Risk Factors and elsewhere in our most recently filed Annual Report on Form 10-K which was filed with the Securities and Exchange Commission on the date of this release, March 28, 2024. These forward-looking statements speak only as of the date hereof and should not be unduly relied upon. Telesis Bio disclaims any obligation to update these forward-looking statements.

    Contact:

    William J. Kullback

    Chief Financial Officer

    [email protected]

             
    Telesis Bio Inc.

    Selected Statements of Operations Financial Data

    (in thousands, except per share amounts)
             
     (unaudited)       
     Three Months Ended 

    December 31,
      Twelve Months Ended 

    December 31,
     
     2023  2022  2023  2022 
    Revenue:           
    Product sales$1,585  $3,482  $9,691  $10,913 
    Service revenue 1,438   1,609   6,291   7,121 
    Collaboration revenue 3,304   3,463   8,690   6,650 
    Royalties and other revenue 650   915   2,837   2,751 
    Total revenue 6,977   9,469   27,509   27,435 
    Cost of revenue 2,228   3,023   10,559   11,840 
    Gross Profit 4,749   6,446   16,950   15,595 
    Operating expenses:           
    Research and development 3,669   4,139   17,496   23,460 
    Sales and marketing 3,604   4,681   13,514   16,489 
    General and administrative 3,568   5,510   21,090   22,131 
    Goodwill impairment 11,389   —   11,389   — 
    Total operating expenses 22,230   14,330   63,489   62,080 
    Loss from operations (17,481)  (7,884)  (46,539)  (46,485)
    Interest income 417   348   1,743   738 
    Interest expense (514)  (611)  (3,105)  (1,955)
    Change in fair value of derivative liabilities 5   29   331   8 
    Loss on extinguishment of debt —   —   —   (727)
    Other expense, net (111)  (8)  (130)  (26)
    Provision for income taxes (3)  (6)  (24)  (24)
    Net loss$(17,687) $(8,132) $(47,724) $(48,471)
    Less: redeemable convertible preferred stock dividends (579)  —   (1,300)  — 
    Net loss attributable to common stockholders$(18,266) $(8,132) $(49,024) $(48,471)
    Net loss per share attributable to common stockholders—basic and diluted$(0.61) $(0.28) $(1.64) $(1.65)
    Weighted average common stock outstanding—basic and diluted 30,010,395   29,564,157   29,849,832   29,463,361 
                    
                    



          
    Telesis Bio Inc.

    Selected Balance Sheet Financial Data

    (in thousands)
          
     December 31,  December 31, 
     2023  2022 
    Balance Sheet Data:     
    Cash, restricted cash, cash equivalents and short-term investments$19,333  $43,753 
    Working capital 22,167   41,594 
    Total assets 70,411   81,362 
    Total liabilities 40,873   34,797 
    Redeemable convertible preferred stock 29,300   — 
    Accumulated deficit (161,465)  (113,741)
    Total stockholders' equity 238   46,565 





    Primary Logo

    Get the next $TBIO alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $TBIO

    DatePrice TargetRatingAnalyst
    8/4/2021$45.00 → $38.00Neutral
    Roth Capital
    8/3/2021$19.00 → $38.00Market Perform
    SVB Leerink
    8/3/2021Outperform → Market Perform
    William Blair
    7/26/2021$28.00 → $45.00Buy
    Roth Capital
    More analyst ratings

    $TBIO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Roth Capital reiterated coverage on Translate Bio with a new price target

      Roth Capital reiterated coverage of Translate Bio with a rating of Neutral and set a new price target of $38.00 from $45.00 previously

      8/4/21 10:08:32 AM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SVB Leerink reiterated coverage on Translate Bio with a new price target

      SVB Leerink reiterated coverage of Translate Bio with a rating of Market Perform and set a new price target of $38.00 from $19.00 previously

      8/3/21 11:37:09 AM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Translate Bio downgraded by William Blair

      William Blair downgraded Translate Bio from Outperform to Market Perform

      8/3/21 11:20:22 AM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TBIO
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Telesis Bio Announces Licensing Agreement with Regeneron to Adopt Gibson SOLA™ Platform for Rapid On-Site DNA and Gene Synthesis

      New technology has potential to accelerate timelines for therapeutic research and drug development Telesis Bio Inc. (OTC:TBIO), a leading provider of DNA and mRNA synthesis solutions to accelerate therapeutic discovery with fast and flexible on-site automated foundries, today announced a new license agreement with Regeneron Pharmaceuticals, Inc. to deploy Telesis Bio's revolutionary Gibson SOLA™ platform at its R&D core facilities. This will help Regeneron adopt automated, high-throughput, on-demand gene synthesis in their own labs. Using Gibson SOLA at scale is intended to contribute to an agile and efficient approach to biologics discovery. The Gibson SOLA platform has been shown to e

      5/28/25 9:00:00 AM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Telesis Bio Secures up to $21 Million to Accelerate Adoption of Groundbreaking Gibson SOLA Technology for Rapid DNA and mRNA Synthesis

      Telesis Bio, a leading provider of DNA and mRNA synthesis solutions to accelerate therapeutic discovery with fast and flexible on-site automated foundries, today announced that it has entered into a convertible preferred stock purchase agreement (the Purchase Agreement) to sell shares of a new series of convertible preferred stock in a private placement. The financing was led by Novalis LifeSciences and Northpond Ventures and is expected to result in gross proceeds to the Company of up to approximately $21 million. The Company's recently launched proprietary next-generation enzymatic synthesis platform, Gibson SOLA™, allows customers to take full control of their nucleic acid supply-chain,

      3/18/25 9:00:00 AM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Telesis Bio and Beckman Coulter Life Sciences Collaborate to Revolutionize DNA and mRNA Synthesis

      SAN DIEGO, Sept. 25, 2024 (GLOBE NEWSWIRE) -- A new partnership between Telesis Bio and Beckman Coulter Life Sciences, a global leader in laboratory automation and innovation, will create efficient and scalable biofoundries, delivering solutions for sustainable and rapid on-premise synthesis of DNA. This innovative approach enabled by Telesis Bio's Gibson SOLA enzymatic reagent platform running on Beckman Coulter Life Sciences automation to ensures rapid, reliable, and highly scalable production of extremely high-fidelity DNA, empowering researchers to achieve greater productivity and innovation in a wide array of discovery applications. The collaboration integrates Telesis Bio's Gibson

      9/25/24 4:05:00 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TBIO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Krueger Todd was granted 8,390 shares (SEC Form 4)

      4 - Telesis Bio Inc. (0001850079) (Issuer)

      7/26/24 4:07:04 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Golub Steven J was granted 8,390 shares (SEC Form 4)

      4 - Telesis Bio Inc. (0001850079) (Issuer)

      7/26/24 4:06:35 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Director Hlavinka Sarah E. was granted 8,390 shares (SEC Form 4)

      4 - Telesis Bio Inc. (0001850079) (Issuer)

      7/26/24 4:06:03 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TBIO
    SEC Filings

    See more
    • SEC Form 15-12G filed by Telesis Bio Inc.

      15-12G - Telesis Bio Inc. (0001850079) (Filer)

      1/14/25 4:35:26 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form EFFECT filed by Telesis Bio Inc.

      EFFECT - Telesis Bio Inc. (0001850079) (Filer)

      1/7/25 12:15:02 AM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • SEC Form EFFECT filed by Telesis Bio Inc.

      EFFECT - Telesis Bio Inc. (0001850079) (Filer)

      1/7/25 12:15:03 AM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TBIO
    Leadership Updates

    Live Leadership Updates

    See more
    • Telesis Bio Reports Second Quarter and First Half 2024 Financial Results

      SAN DIEGO, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis technology in their own lab, today announced financial results for the second quarter and first half of 2024. Highlights Gibson SOLA – the Company continues to advance its Gibson SOLA reagent platform that enables on-premises automated overnight synthesis of high-fidelity long DNA and mRNA on a variety of liquid handling platforms. The Company's presentation "Enhancing Therapeutic Protein Production with Gibson SOLA Enzymatic DNA Assembly: Pioneeri

      8/7/24 4:05:00 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Vicore Expands and Strengthens its Board of Directors

      STOCKHOLM, SWEDEN / ACCESSWIRE / May 14, 2024 / Vicore Pharma Holding (STO:VICO) Stockholm, May 14, 2024 - Vicore Pharma Holding AB, a clinical-stage biopharmaceutical company unlocking the potential of a new class of drug candidates, angiotensin II type 2 receptor agonists (ATRAGs), is pleased to announce the election of Hans Schikan, PharmD, as the new Chair of the Board of Directors as well as the election of two new Board members, Ann Barbier, MD, PhD and Yasir Al-Wakeel BM, BCh.Hans Schikan has been a member of the Board since 2018 and is a leader in rare disease drug development and strategy. He was previously CEO of Prosensa (NASDAQ:RNA), a company developing therapies for rare diseas

      5/14/24 2:20:00 AM ET
      $KRON
      $MACK
      $MXCT
      $PHVS
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Commercial Physical & Biological Resarch
      Biotechnology: Laboratory Analytical Instruments
    • Telesis Bio Appoints William J. Kullback Chief Financial Officer

      SAN DIEGO, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, has named William J. Kullback as its Chief Financial Officer, effective August 28, 2023. As CFO, Kullback will be responsible for the Company's financial planning and analysis, accounting, internal audit, tax, and treasury functions. "Bill's deep industry knowledge, operational expertise, and extensive financial experience make him ideally positioned to help lead us through the next phase of the Company's growth," said Todd R. Nelson, PhD, CEO, and founder of Telesis Bio. "We are thrilled to welcome Bill to our team and excited to have another lead

      8/29/23 4:05:00 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TBIO
    Financials

    Live finance-specific insights

    See more
    • Telesis Bio Reports First Quarter 2024 Financial Results

      SAN DIEGO, May 09, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, today announced financial results for the first quarter of 2024.  In discussing results, recently appointed President and CEO Eric Esser said, "I am pleased with our performance as we execute against our strategy to focus on Gibson SOLA and BioXp mRNA solutions. Our BioXp mRNA offerings continue to gain traction and are delivering real improvements in speed and simplicity to our customers in their discovery workflows. I'm also excited abo

      5/9/24 4:05:00 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Telesis Bio Reports Fourth Quarter and Full Year 2023 Financial Results

      SAN DIEGO, March 28, 2024 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leading provider of RNA and DNA solutions enabling researchers to accelerate therapeutic discovery through advanced, flexible, and rapid automated synthesis in their own lab, today announced financial results for the fourth quarter and year ended December 31, 2023. Results highlight strong BioXp® kit sales, expanding gross margin and reduced operating expense. In discussing the results, Todd R. Nelson Ph.D., Founder and CEO of Telesis Bio said, "I'm pleased with our operating execution in a challenging macro environment during 2023. Our company experienced record BioXp kits sales and expanding gross margin aga

      3/28/24 4:05:00 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Telesis Bio Reports Third Quarter 2023 Financial Results

      SAN DIEGO, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Telesis Bio Inc. (NASDAQ:TBIO), a leader in automated multi-omic and synthetic biology solutions, today reported financial results for the third quarter of 2023. "This quarter, we continued to drive adoption of our instruments and kits, make progress against important collaborations, advance our mRNA strategy, and strengthen both our Board of Directors and Management Team," said Todd R. Nelson, PhD, CEO, and founder of Telesis Bio. Highlights Strengthened board of directors and management team: Appointed Greg Herrema, Senior Advisor to Novalis LifeSciences to the Telesis Bio board of directors in October 2023. Mr. Herrema's distinguished car

      11/13/23 4:22:00 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials

    $TBIO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Telesis Bio Inc.

      SC 13G/A - Telesis Bio Inc. (0001850079) (Subject)

      11/8/24 8:23:25 AM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13D/A filed by Telesis Bio Inc.

      SC 13D/A - Telesis Bio Inc. (0001850079) (Subject)

      11/6/24 4:50:27 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials
    • Amendment: SEC Form SC 13D/A filed by Telesis Bio Inc.

      SC 13D/A - Telesis Bio Inc. (0001850079) (Subject)

      11/6/24 4:05:27 PM ET
      $TBIO
      Biotechnology: Laboratory Analytical Instruments
      Industrials